Encapsulated Engineered RPE Cells for Immune Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating diseases and disorders with implanted cells, tissues, and devices face challenges in modulating the immune response effectively, which affects the fidelity and function of these implants.
Innovation Solution
Development of cell compositions comprising engineered retinal pigment epithelial (RPE) cells that produce therapeutic agents, such as polypeptides, and are encapsulated in a suitable material for administration, allowing for controlled immune response modulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If implanted cells are used to treat diseases, then therapeutic benefit is provided, but immune response adversely affects cell fidelity and function
Solution Approach 1:
The patent uses encapsulating materials as an intermediary barrier between the implanted cells and the host immune system. The encapsulation matrix physically separates the cells from immune cells while allowing selective passage of nutrients, waste, and therapeutic products, thereby protecting cell function from immune-mediated damage.
Solution Approach 2:
The patent converts the harmful immune response into a beneficial effect by engineering the encapsulation matrix to selectively modulate immune cell behavior. The matrix allows beneficial immune modulation while blocking harmful immune attacks, effectively turning the immune system's activity into a protective mechanism for the implanted cells.
2Duration of action of moving object
If cells are implanted to produce therapeutic agents, then disease treatment is achieved, but maintaining cell viability and production over extended periods is challenging
Solution Approach 1:
The patent incorporates protective encapsulation materials that provide beforehand cushioning against immune attacks and environmental stressors. This pre-established protection allows cells to maintain viability and continue producing therapeutic agents for extended periods without being compromised by external harmful factors.
Solution Approach 2:
The patent utilizes parameter changes in the encapsulation matrix properties, such as porosity, degradation rate, and mechanical strength, to optimize the microenvironment for long-term cell survival. By adjusting these parameters, the system maintains cell viability and therapeutic production over extended durations while adapting to changing physiological conditions.
Data Source
AI summary
Described herein are cell compositions comprising an active cell (e.g., an engineered active cell, e.g., an engineered RPE cell) or derivatives thereof, as well as compositions, pharmaceutical products, and implantable elements comprising an active cell, and methods of making and using the same. The cells and compositions may express a therapeutic agent useful for the treatment of a disease, disorder, or condition described herein.